Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML
A body of in vitro evidence suggests that use of granulocyte-macrophage colony-stimulating factor (GM-CSF) might increase the in vivo sensitivity of leukemic myeloblasts to daunorubicin-cytosine arabinoside (ara-C) chemotherapy [1–4]. If so, administration of GM-CSF prior to and during administration of daunorubicin/ara-C might overcome the resistance to therapy that is characteristic of acute myeloid leukemia (AML). This resistance is most obvious in patients with abnormalities of chromosomes 5, 7, (−5, −7, 5q-, 7q-) who frequently fail even to enter initial complete remission (CR), but it is also a major problem in patients with other aneuploidies (except INV(16), t (15; 17), or t (8; 21)), or with a normal karyotype or insufficient metaphases for analysis .While the majority of these patients enter CR, their remissions rarely last more than 2 years.
KeywordsLeukemia Anemia Oncol Resis Sine
Unable to display preview. Download preview PDF.
- 2.Hiddemann W, Kiehl M, Schleyer E, Woermann B, Zuehlsdorf M, Buechner T (1989) Stimulating effect of GM-CSF and IL-3 on the metabolism and cytotoxic activity of cytosine arabinoside in leukemia blasts from patients with acute myeloid leukemia. Blood 74 (Suppl 1): 230aGoogle Scholar
- 5.Keating M, Cork A, Broach Y, Smith T, Walters R, McCredie K, Trujillo J, Freireich E (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res: 119–133Google Scholar